QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
VENLO, the Netherlands & TEL AVIV, Israel--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.
The acquisition adds Franklin, Genoox's flagship cloud-based community platform, to the QIAGEN Digital Insights (QDI) portfolio, strengthening QIAGEN's leadership in genetic interpretation for clinical genomics applications.
Franklin empowers labs to analyze next-generation sequencing (NGS) data – from targeted gene panels to whole exome and genome sequencing (WES/WGS) - and delivers real-time, AI-driven insights to support clinical decision-making. Applications range from diagnosing genetic disorders and informing cancer treatments to supporting family planning decisions.
The platform is currently used by more than 4,000 healthcare organizations in over 50 countries and has powered more than 750,000 case interpretations to date.
'The acquisition of Genoox brings together two complementary strengths to better serve clinical testing laboratories,' said Thierry Bernard, CEO of QIAGEN. 'Franklin's AI-powered solution offers exciting opportunities for labs to rapidly identify the most clinically relevant insights and help improve patient outcomes. Combined with QIAGEN's trusted clinical knowledge and interpretation tools, the addition of Franklin to our portfolio will enable QIAGEN to better address the challenges of our customers who are seeking easy-to-use, rapid and scalable clinical decision-support solutions.'
'Joining QIAGEN marks a major milestone in our mission to make genomic data more accessible and actionable,' said Amir Trabelsi, Co-founder and CEO of Genoox. 'Franklin will benefit from QIAGEN's global reach and scientific leadership as we scale to support more labs and patients around the world. As part of QIAGEN, we can together drive the next wave of precision medicine.'
The acquisition also creates a path to integrate QIAGEN's genomic content into the Franklin platform. This includes the Human Gene Mutation Database (HGMD), the Catalogue of Somatic Mutations in Cancer (COSMIC), and the QIAGEN Knowledge Base (QKB) – all of which power the company's leading QCI Interpret and QCI Precision Insights solutions. These future integrations will expand Franklin's interpretive power, and in turn improving diagnostic yield, turnaround time and scalability for clinical labs.
Transaction summary
QIAGEN has acquired Genoox for $70 million in cash and eligible for additional milestone payments of up to $10 million. The acquisition is expected to generate approximately $5 million of sales in 2025 for QIAGEN and have a neutral impact on adjusted EPS.
About Genoox
Founded in 2014 and headquartered in Tel Aviv, Israel, Genoox provides cloud-based tools for genomic data interpretation in clinical and research settings. Its Franklin platform supports real-time, evidence-based analysis of hereditary variants, helping clinicians, researchers, and genetic professionals make informed decisions. Franklin combines AI-driven interpretation with a global community network to improve access to actionable genetic insights. For more information, visit www.genoox.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit https://www.qiagen.com.
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Boeing's High-Wire Comeback: Can Ortberg Keep the Revival on Track?
Boeing (NYSE:BA) is mounting what could be its most consequential turnaround in decades, with CEO Kelly Ortberg at the helm just ten months into a job many wouldn't touch. Since taking over, Ortberg has steadied the production line, particularly the embattled 737 Max, and helped rebuild investor confidencereflected in a 22% rally in the stock this year. But with lingering safety concerns, regulatory scrutiny, and $1.1 billion paid to avoid prosecution over prior crashes, the shadow of Boeing's past still looms large. As Ortberg heads to the Paris Air Show, he faces a pivotal test of Boeing's progress and promises. Warning! GuruFocus has detected 6 Warning Signs with BA. Ortberg is leaning into his supplier background to reset Boeing's frayed industrial relationships. He's publicly criticized the company's aggressive Partnering for Success program that left vendors squeezed and soured. Now, with FAA-imposed production caps and rising delivery pressure, rebuilding trust with suppliers is essential if Boeing wants to scale outputand cash flow. May marked the first time since 2020 that Boeing produced 38 Max jets in a single month, but future rate increases still hinge on regulatory greenlights. Meanwhile, industry leaders cautiously believe Boeing is turning the corner, but note that execution, not words, will be the true signal. Still, culture may be the hardest fix. A recent employee survey revealed a steep drop in morale and trust in leadership compared to a decade ago. Ortberg is moving the needle, instituting new values, mandating executive accountability, and committing to worker engagementincluding direct union meetings with leadership. But critics argue change has been too slow, and victim families from the Max crashes continue to challenge Boeing's legal settlement in court, calling it a cost of doing business. Analysts warn: despite green shoots, one misstep could undo years of effortreminding investors just how fragile Boeing's second chance really is. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
Here's Why Archer Aviation Stock Is Soaring Today
The White House is officially encouraging the development of the nation's air taxi industry. A recent executive order calls for at least one private company to be involved in shaping the launch and future of this business. Even though Archer isn't guaranteed to be a part of this laying of regulatory groundwork, regulatory hurdles may have just been lowered. 10 stocks we like better than Archer Aviation › Shares of Archer Aviation (NYSE: ACHR) rekindled their choppy recovery rally today, up 11.7% as of 2:33 p.m. ET. While the reason for the big move doesn't directly translate into real revenue or profit progress, it certainly makes both much more likely than was first anticipated. Credit President Donald Trump, mostly. With an executive order signed late Friday, the U.S. president has hastened the advent of the United States' electric air taxi industry that will provide personal mobility from one specific inner-city location to another. The order explicitly requests that the Secretary of Transportation begin laying the groundwork for the development of an official eVTOL (electric vertical takeoff and landing) pilot program that includes the participation of at least one "private sector partner with demonstrated experience in eVTOL aircraft development, manufacturing, and operations." Archer Aviation qualifies. Its so-called Midnight aircraft capable of flying like an airplane but taking off and landing like a helicopter is not only fully electrically powered, but has already made several hundred successful test flights. Moreover, the company itself is already laying the groundwork for commercial operations in New York and Los Angeles. Transportation Secretary Sean Duffy could readily meet President Trump's accelerated timeline goals using Archer's work to date. There's no assurance that Archer Aviation will be one of the private sector outfits brought into this regulatory fold, of course. There are others that qualify, like Joby Aviation. There's also no reason to suspect that only one private operator will become involved in this official test initiative though. And, given that Archer is developing a version of its Midnight aircraft specifically for the U.S. Air Force, its technology also already arguably has the U.S. government's unofficial approval. And, whether or not Archer is selected for involvement with the Secretary of Transportation's new mandate, there's more than ample opportunity for more than one air taxi service provider in the U.S. alone, not to mention overseas. Industry research outfit Global Market Insights believes the world's air taxi market is poised to grow at an average annualized pace of more than 20% per year through 2032, led by North America. More important to interested investors, Trump's executive order creates more room and reason for Archer Aviation stock to continue rallying from here. Although the start-up is still years away from profitable operations -- and as such still poses tremendous risk to its shareholders -- the potential upside is commensurate with this risk. Before you buy stock in Archer Aviation, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Archer Aviation wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Here's Why Archer Aviation Stock Is Soaring Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
PsiQuantum Eyes $750M Raise As BlackRock Doubles Down On Light-Based Supercomputers Amid Nvidia's Quantum Reversal
Quantum computing startup PsiQuantum is seeking to raise at least $750 million in a funding round led by BlackRock (NYSE:BLK), aiming to double its valuation to $6 billion, San Francisco Business Times reports. The Palo Alto-based company is developing a fault-tolerant quantum computer using photonic qubits, leveraging traditional semiconductor manufacturing techniques. According to PsiQuantum's website, the company's approach involves using photons as qubits, allowing for scalability through existing chip fabrication processes. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Maximize saving for your retirement and cut down on taxes: . PsiQuantum is collaborating with the governments of Australia and the U.S. to build quantum computing facilities in Brisbane and Chicago, respectively, Reuters reports. According to the Australian Financial Review, the company has secured $617 million in funding in Australia from federal and Queensland governments to construct a commercial quantum computer. In the U.S., PsiQuantum plans to build a 300,000-square-foot facility in Chicago's Illinois Quantum and Microelectronics Park, supported by more than $500 million in anticipated public funding, The Quantum Insider says. The initiatives underscore PsiQuantum's commitment to advancing quantum computing infrastructure globally. PsiQuantum manufactures its quantum chips at GlobalFoundries' facility in New York, utilizing photonic technology developed for fiber-optic communications, Reuters reports. Trending: Wall Street's Missing This AI Surgical Tech — You Don't Have To. According to The Quantum Insider, the company has introduced the Omega quantum photonic chipset, designed for utility-scale quantum computing, featuring high-performance photonic components. Additionally, PsiQuantum has developed high-speed optical switches and improved photon detectors to enhance quantum circuit performance. To boost efficiency, PsiQuantum implemented a compilation technique known as active volume compilation, aiming to reduce application run times by approximately 50-fold, The Quantum Insider says. BlackRock, which led PsiQuantum's previous $450 million round, is returning as lead investor, signaling sustained institutional confidence. According to San Francisco Business Times, other major backers include Microsoft's (NASDAQ:MSFT) venture arm M12, Atomico, Founders Fund, Playground Global, Temasek Holdings, and FPV Ventures. According to The Information, Nvidia (NASDAQ:NVDA) is in advanced discussions to invest in PsiQuantum, signaling a strategic shift in its quantum computing approach. This potential investment follows Nvidia CEO Jensen Huang's announcement of a new quantum computing research lab in Boston, in collaboration with Harvard and MIT, Reuters January, Huang rocked the sector by suggesting quantum computers were at least 20 years from viability, sending quantum-related stocks tumbling. But just weeks later, during Nvidia's 'Quantum Day' at its GTC conference in San Jose, California, Huang reversed course, admitting his earlier comments were off the mark, according to CNBC. That shift helped reignite interest in companies like PsiQuantum, which now stand to benefit from the renewed optimism and visibility. While competitors such as Google, IBM (NYSE:IBM), Intel (NASDAQ:INTC), Honeywell (NASDAQ:HON), and Rigetti Computing (NASDAQ:RGTI) continue to push their own quantum architectures, PsiQuantum's photonic approach is seen by many as a promising alternative, San Francisco Business Times says. PsiQuantum's funding round reflects growing investor confidence in the company's photonic quantum computing technology. The company's innovative approach may position it as a key player in the race to develop practical quantum computing solutions. Read Next: Here's what Americans think you need to be considered Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article PsiQuantum Eyes $750M Raise As BlackRock Doubles Down On Light-Based Supercomputers Amid Nvidia's Quantum Reversal originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
